Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
14:16
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

WFH 2012 World Congress

 

8-12 July, 2012 Paris, FRANCE
Sponsored by:

FAQs
   
Discussion forum - WFH 2012 World Congress
    Topic - Inhibitors Pathogenesis, Prevention and Treatment

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Identification of potential T-cell epitopes in factor VIII using peptide microarrays  Kathleen Pratt 1      6/26/2012 4:10:00 PM  
Prospective ADVATE Immune Tolerance Induction Registry (PAIR) in Hemophilia APatients with Inhibitors: Interim Report  Gerald Spotts 1      6/26/2012 12:20:00 AM  
Genetic risk factors for inhibitor development in a Brazilian severe hemophiliaA population  Margareth Ozelo 1      6/25/2012 10:03:00 PM  
IgG4 subclass of anti-FVIII antibodies is correlated to high-titer inhibitor,whereas IgG1 subclass is related to low-titer inhibitor in hemophilia Apatients.  Margareth Ozelo 1      6/25/2012 5:38:00 PM  
F8 genotype and not polymorphisms in IL10, TNFA and CTLA4 influences inhibitor development in Argentine patients with severe HA.  Liliana Rossetti 1      6/25/2012 5:15:00 PM  
Presence and evolution of anti-factor VIII (FVIII) catalytic activity in severe,mild or moderate hemophilia patients with FVIII inhibitors  Sandrine Grosbois 1      6/25/2012 5:04:00 PM  
Circumcision experience in severe hemophilia patients with inhibitors  Ilgen Sasmaz 1      6/25/2012 3:16:00 PM  
Impact of HLA and cytokines polymorphisms on inhibitors development in childrenwith severe Haemophilia A  Helen Pergantou 1      6/25/2012 12:42:00 PM  
Sequential therapy with activated prothrombin complex concentrate andrecombinant factor VIIa in the treatment of unresponsive bleeding in patientswith hemophilia and inhibitors in a single center experience  Young Shil Park 1      6/25/2012 6:23:00 AM  
Genotype-phenotype Correlation in Hemophilia A and Risk of Inhibitors of F8 genemutations  jinyoung choi 1      6/25/2012 6:17:00 AM  
Identification of potential T-cell epitopes in factor VIII using peptidemicroarrays  Kathleen Pratt 1      6/25/2012 12:11:00 AM  
Prevalence of inhibitor in a prospective cohort of hemophilic children under 4years of age from a single center.  Florencia Tisi Baña 1      6/24/2012 8:03:00 PM  
ALLELE POLYMORPHISMS OF IMMUNE RESPONSE GENES IN SEVERE HAEMOPHILIA A PATIENTSWITH INHIBITORS IN UKRAINE  Oleksandra Stasyshyn 1      6/24/2012 4:05:00 PM  
Successful Immune Suppression Followed by Immune Tolerance Induction in a Factor9 Patient Who had Developed an Anaphylactic Reaction to Factor 9.  Nancy Hodgson 1      6/22/2012 10:58:00 PM  
Successful use of negative pressure wound therapy in a patient with severeHemophilia A and an inhibitor  Vicky Hanneman 1      6/22/2012 10:34:00 PM  
Successful low-dose immune tolerance induction regimen using multiple plasma-derived factor VIII concentrates.  Marina Pereira Colella 1      6/22/2012 9:45:00 PM  
HOW MANY PATIENTS WITH HIGH-RESPONDING INHIBITORS DO/DID NOT UNDERGO IMMUNETOLERANCE INDUCTION IN ITALY? WHY NOT?  Antonio Coppola 1      6/22/2012 4:02:00 PM  
Intracranial Hemorrhage (ICH) in a 5-years-old Child with Severe Hemophilia Band Inhibitors with Anaphylaxis: Treatment Issues  Carvalho Manuela 1      6/22/2012 2:24:00 PM  
USE OF FACTOR VIII CONCENTRATES IN LIFE-THREATENING BLEEDING IN HEMOPHILICPATIENTS WITH INHIBITOR  Hugh C Kim 1      6/22/2012 8:03:00 AM  
Experience of surgery in patients with haemophilia with inhibitors  Tatiana Polyanskaya 1      6/21/2012 1:54:00 PM  
RISK OF BLEEDING AND INHIBITOR DEVELOPMENT AFTER CIRCUMCISION OF PREVIOUSLYUNTREATED(PUPs) OR MINIMALLY TREATED(MTPs) SEVERE HEMOPHILIA A PATIENTS  mohsen el alfy 1      6/21/2012 12:55:00 PM  
Resolution of Nephrotic Syndrome Following Rituximab Therapy in a PatientUndergoing Immune Tolerance Induction  Susan Kearney 1      6/20/2012 6:09:00 PM  
Plasma-exchange and immunosuppressive therapy in a patient with mild hemophiliaA and inhibitors complicated by severe muscular bleeding and compartmentalsyndrome  Gabriella Gamba 1      6/13/2012 3:32:00 PM  
Effect of in vivo induction of regulatory T cells during immune toleristaion on FVIII inhibitor anamnestic response  Simon Brown 1      6/13/2012 7:27:00 AM  
Prevalence of inhibitor antibodies in the Mazandaran(North of Iran) haemophiliaA population.  Hassan Mahmoodi Nesheli 1      6/10/2012 9:05:00 PM  
A Canadian survey on the incidence and risk factors for inhibitor development insevere hemophilia A PUPs: 2005-2010.  Georges-Etienne Rivard 1      6/10/2012 5:04:00 PM  
Case series report . low-dose immune tolerance (ITI) in Iran  shirin Tehrani Tarighat 1      6/6/2012 7:40:00 AM  
Factor VIII product-dependent recognition of anti-factor VIII antibodies  Saulius Butenas 1      5/29/2012 4:04:00 PM  
Plasma Exchange and Continuous Infusion of Factor VIII for Life-Saving Surgeryin Hemophilia A with High-Titer Inhibitor: Two Case Reports  Rungrote Natesirinilkul 1      5/14/2012 6:15:00 PM  
       




Most viewed poster for this congress
Poster: 243
Visits: 2712
Title: Use of the Exergaming (Nintendo Wii) in the Rehabilitation of Patients withHemophilia.
Authors: JANAINA BOSSO JOSÉ DA SILVA , Rafael Fagnani, Egritti de Oliveira Zacarias da Silva,Marcia Aparecida Picoloto Matta, Margareth Castro Ozelo
Centre: UNICAMP

Poster most viewed in this topic
Poster: 133
Visits: 881
Title: A Canadian survey on the incidence and risk factors for inhibitor development insevere hemophilia A PUPs: 2005-2010.
Authors: Georges-Etienne Rivard , M. Carcao, C. Infante-Rivard, A.M. StainE. Paradis, J. Teitel
Centre: CHU Sainte-Justine, Montréal, QC, Canada


 
Sponsored by:
PosterSessionOnline
Logo Draft
 
Logo Cert